The I-HIT-MED registry records patients with rare brain or spinal cord tumours.
The University Medical Centre Hamburg-Eppendorf in Germany is responsible for the international registry. In Switzerland, the Swiss Paediatric Oncology Group (SPOG) is responsible for managing the registry.
Background
The I-HIT-MED registry records patients with rare brain or spinal cord tumours. These are medulloblastomas, ependymal, pineal region or choroid plexus tumours, as well as other rare tumours. In Switzerland, approximately 15 to 20 children, adolescents and young adults are expected to participate in this international registry study each year.
Why is the I-HIT-MED research project necessary?
The research project aims to improve future treatment for patients with rare brain and spinal cord tumours. To achieve this, researchers monitor the therapies used, investigate the tumour biology, and document the late effects.
At the same time, participating children, adolescents and young adults benefit from having their diagnosis verified by an independent reference centre, which also advises the treatment team regarding therapy. This additional quality control can be beneficial for the participants.
In short
-
The researchers are using the registry to analyse the therapies, late effects and biology of certain brain and spinal cord tumours in children, adolescents and young adults.
-
The research project aims to improve future treatments for children, adolescents and young adults with rare brain and spinal cord tumours.
-
An international reference center ensures the diagnosis of the participating children, adolescents and young adults and provides therapeutic advice to the treating physicians. This additional quality assurance is beneficial for the young patients.
